Abstract:Phosphodiesterase type 5 (PDE5) inhibitors are clinically indicated for the treatment of erectile dysfunction, pulmonary hypertension and various other diseases. In this work, both ligand- and receptor-based three-dimensional quantitative structure–activity relationship (3D-QSAR) studies were carried out using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques on 122 pyrazinone derivatives as PDE inhibitors. The resultant optimum 3D-QSAR model exhibits a proper predictive ability as indicated by the statistical results of Q2 of 0.584, Rncv2 of 0.884 and Rpre2 of 0.817, respectively. In addition, docking analysis and molecular dynamics (MD) simulation were also applied to elucidate the probable binding modes of these inhibitors. Our main findings are: (1) Introduction of bulky, electropositive and hydrophobic substituents at 12- and 19-positions can increase the biological activities. (2) N atom at 8-position is detrimental to the inhibitor activity, and the effect of N atoms at 5- and 6-positions on compound activity is co-determined by both the hydrophobic force and the π–π stacking interaction. (3) Bulky and hydrophilic substitutions are favored at the 27-position of ring D. (4) Electronegative and hydrophilic substitutions around 5- and 6-positions increase the inhibitory activity. (5) Hydrophobic forces and π–π stacking interaction with Phe786 and Phe820 are crucial in determining the binding of pyrazinone derivatives to PDE5. (6) Bulky substitutions around ring C favors selectivity against PDE11, while bulky groups near the 21-position disfavor the selectivity. The information obtained from this work can be utilized to accurately predict the binding affinity of related analogues and also facilitate future rational designs of novel PDE5 inhibitors with improved activity and selectivity.

Identification of Pyrroloimidazoles As Potential Inhibitors of WDR5-WIN-Site by 3D-QSAR Molecular Simulation

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Computational Studies of Novel Aniline Pyrimidine WDR5-MLL1 Inhibitors: QSAR, Molecular Docking, and Molecular Dynamics Simulation

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

3d-Qsar Studies Of Dihydropyrazole And Dihydropyrrole Derivatives As Inhibitors Of Human Mitotic Kinesin Eg5 Based On Molecular Docking

3D-QSAR, Molecular Docking and Molecular Dynamics Simulations Study of 3-Pyrimidin-4-yl-oxazolidin-2-one Derivatives to Explore the Structure Requirements of Mutant IDH1 Inhibitors

Identification of 5-Thiocyanatothiazol-2-amines Disrupting WDR5-MYC Protein-Protein Interactions.

Screening and Optimization of Phage Display Cyclic Peptides Against the WDR5 WBM Site

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: An in silico analysis

3D-Qsar and Docking Studies on Pyrrolopyrimidine Derivatives As Lim-Kinase 2 Inhibitors

Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5

Receptor and ligand-based 3D-QSAR study on a series of pyrazines/pyrrolidylquinazolines as inhibitors of PDE10A enzyme

A Combined Molecular Modeling Study On A Series Of Pyrazole/Isoxazole Based Human Hsp90 Alpha Inhibitors

Molecular docking-based 3D-QSAR studies of pyrrolo[3,4-c]pyrazole derivatives as Aurora-A inhibitors

A Combined Molecular Modeling Study on a Series of Pyrazole/isoxazole Based Human Hsp90α Inhibitors

Molecular Docking, QSAR and Molecular Dynamics Simulation on Phosphorus Containing Pyrimidines As CDK9 Inhibitors

3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents

3D-QSAR study of pyrrolidine derivatives as matrix metalloproteinase-2 inhibitors

3D-QSAR and Docking Studies of 3-Pyridine Heterocyclic Derivatives As Potent PI3K/mTOR Inhibitors